Examining LRG Levels to Predict Remission in Ulcerative Colitis
What is the Level of Serum Leucine-rich α 2-glycoprotein (LRG) Which Predicts Histologic Remission in Patients With Ulcerative Colitis?
Showa Inan General Hospital · NCT06372613
This study is testing if measuring a specific protein in the blood can help predict when people with ulcerative colitis will go into remission.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 20 Years to 90 Years |
| Sex | All |
| Sponsor | Showa Inan General Hospital (other) |
| Locations | 1 site (Komagane) |
| Trial ID | NCT06372613 on ClinicalTrials.gov |
What this trial studies
This study investigates the potential of serum leucine-rich α 2-glycoprotein (LRG) as a noninvasive biomarker for predicting histologic remission in patients with ulcerative colitis (UC). Patients with active UC will have their serum LRG levels measured, and colonoscopy with histology will be performed when histologic remission is anticipated, regardless of symptoms or serum LRG values. The study aims to evaluate the diagnostic ability of LRG through analysis of the area under receiver operating characteristic (ROC) curves, providing insights into disease activity monitoring.
Who should consider this trial
Good fit: Ideal candidates for this study are patients currently experiencing active ulcerative colitis.
Not a fit: Patients who are not currently experiencing active ulcerative colitis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable noninvasive method for monitoring remission in ulcerative colitis patients.
How similar studies have performed: While the use of biomarkers in ulcerative colitis is an area of ongoing research, this specific approach using LRG is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * active UC patients Exclusion Criteria: * None
Where this trial is running
Komagane
- Showa Inan General Hospital — Komagane, Japan (RECRUITING)
Study contacts
- Study coordinator: Akia Horiuchi
- Email: horiuchi.akira@sihp.jp
- Phone: 09021684311
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Ulcerative Colitis in Histologic Remission